Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's
macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects
(good and bad) it has on the cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Millennium Pharmaceuticals, Inc.